Interferon beta in the treatment of multiple sclerosis: Mechanisms of action

Neurology

Volumn 51, Issue 3, 1998, Pages 682-689

  Yong, V Wee ^c   Chabot, Sophie ^d   Stuve, Olaf ^a   Williams, Gary ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BAYER AG   (Germany)

^c Neuroscience Research Group   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CHEMOKINE; MATRIX METALLOPROTEINASE;

ANTIGEN PRESENTATION; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; IMMUNOMODULATION; LEUKOCYTE MIGRATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0008376732     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.3.682     Document Type: Review

References (80)

1. IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Paty DW, Li DKB, UBC MS/MRI Study Group, IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
3. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12-18.
4. IFN-β Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
5. Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
6. Fernández O, Antiquëdad A, Arbizu T, et al. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial. Multiple Sclerosis 1995;1:S67-S69.
7. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996;64:91-100.
8. Stinissen P, Raus J, Zhang J. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit Rev Immunol 1997;17: 33-75.
9. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997;120:865-916.
10. Arnason BGW, Dayal A, Qu ZX, Jensen MA, Genc K, Reder AT. Mechanisms of action of interferon-β in multiple sclerosis. Springer Semin Immunopathol 1996;18:125-148.
11. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
12. Hall GL, Compston A, Scolding NJ. Beta-interferon and multiple sclerosis. Trends Neurosci 1997;20:63-67.
13. Noronha A, Toscas A, Jensen MA. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol 1993;46:145-154.
14. Horwitz MS, Evans CF, McGavern DB, Rodriguez M, Oldstone MBA. Primary demyelination in transgenic mice expression interferon-γ. Nat Med 1997;3:1037-1041.
15. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-450.
16. Yong VW, Antel JP. Major histocompatibility complex molecules on glial cells. Semin Neurosci 1992;4:231-240.
17. Barna BP, Chou SM, Jacobs B, Yen-Lieberman B, Ransohoff RM. Interferon-β impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol 1989;23:45-53.
18. McLaurin J, Antel JP, Yong VW. Immune and non-immune actions of interferon-β-1b on primary human neural cells. Multiple Sclerosis 1995;1:10-19.
19. Hall GL, Wing MG, Compston DAS, Scolding NJ. β-interferon regulates the immunomodulatory activity of neonatal rodent microglia. J Neuroimmunol 1997;72:11-19.
20. Jiang H, Milo R, Swoveland P, Johnson KP, Panitch H, Dhib-Jalbut S. Interferon β-1b reduced interferon-γ-induced antigen-presenting capacity of human glial and B cells. J Neuroimmunol 1995;61:17-25.
21. Gene K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b. J Clin Invest 1997;99:2664-2671.
22. Rep MHG, Hintzen RQ, Polman CH, van Lier RAW. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 1996;67:111-118.
23. Trinchieri G. Immunobiology of interleukin-12. Immunol Res 1998;17:269-278.
24. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18:263-265.
25. Smeltz RB, Swanborg RH. Concordance and contradiction concerning cytokines and chemokines in experimental demyelinating disease. J Neurosci Res 1998;51:147-153.
26. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
27. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994;24:1434-1440.
28. Drulovic J, Mostarica-Stojkovic M, Levic Z, et al. Interleukin-12 and tumor necrosis factor-α levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 1997; 147:145-150.
29. Correale J, Gilmore W, McMillan M, et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 1995;154:2959-2968.
30. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor - a messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
31. Nicoletti F, Patti F, Cocuzza C, et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 1996;70:87-90.
32. Romagnani S, Parronchi P, D'Elios MM, et al. An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 1997; 113:153-156.
33. Brosnan CF, Canella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions. Neurol 1995;45(suppl 6):S16-S21.
34. Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996;274:2054-2057.
35. Rudick RA, Ransohoff RM, Peppler R, Medendorp SV, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40: 618-627.
36. McRae BL, Picker LJ, van Seventer GA. Human recombinant interferon-β influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors. Eur J Immunol 1997;27:2650-2656.
37. Chabot S, Williams G, Yong VW. Microglial production of TNF-α is induced by activated T lymphocytes: involvement of VLA-4 and inhibition by interferonβ-1b. J Clin Invest 1997; 100:604-612.
38. Louis J-C, Magal E, Takayama S, Varon S. CNTF protection of oligodendrocytes against natural and tumor necrosis factor α-induced death. Science 1993;259:689-692.
39. Jenkins HG, Ikeda H. Tumor necrosis factor causes an increase in axonal transport of protein and demyelination in the mouse optic nerve. J Neurol Sci 1992;108:99-104.
40. Ruddle NH, Bergman CM, McGarth KM, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172: 1193-1200.
41. Liu J, Marion MW, Wong G, et al. TNF is a potent antiinflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83.
42. Yednock T, Cannon C, Fritz L, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992; 356:63-66.
43. Kuchroo V, Martin C, Greer J, Ju ST, Sobel RA, Dorf ME. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol 1993;151: 4371-4382.
44. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway Jr CA. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;177:57-68.
45. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37: 611-619.
46. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66.
47. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 1998;279:381-384.
48. Cannella B, Cross AH, Raine CS. Adhesion-related molecules in the CNS. Upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. Lab Invest 1991;65:23-31.
49. Cannella B, Raine C. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435.
50. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann Neurol 1997;41:669-674.
51. Corsini E, Gelati M, Dufour A, et al. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study. J Neuroimmunol 1997;79:76-83.
52. Dhib-Jalbut S, Jiang H, Williams GJ. The effect of interferon β-1b on lymphocyte-endothelial cell adhesion. J Neuroimmunol 1996;71:215-222.
53. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445.
54. Kunkel SL, Strieter RM, Lindley IJD, Westwick J. Chemokines - new ligands, receptors and activities. Immunol Today 1996;16:559-561.
55. Ransohoff RM, Hamilton TA, Tani M, et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 1993; 7:592-600.
56. Berman JW, Guida MP, Warren J, Amat J, Brosnan CF. Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat. J Immunol 1996; 156:3017-3023.
57. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995;155:5003-5010.
58. Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K. Macrophage inflammatory protein-1α in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neurol Sci 1995;129:223-227.
59. Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997;58:52-59.
60. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the central nervous system. Trends Neurosci 1998;21:75-80.
61. Matrisian LM. The matrix-degrading metalloproteases. Bioessays 1992;14:455-463.
62. Uhm JH, Dooley NP, Villemure JG, Yong VW. Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can J Neurol Sci 1997;24:3-15.
63. Stuve O, Dooley NP, Uhm JH, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863.
64. Xia M, Leppert D, Hauser SL, et al. Stimulus specificity of matrix metalloprotease dependence of human T cell migration through a model basement membrane. J Immunol 1996;156: 160-167.
65. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389.
66. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300-309.
67. Cuzner ML, Gveric D, Strand C, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion formation. J Neuropathol Exp Neurol 1996;55:1194-1204.
68. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177-2182.
69. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflam Res 1995;44:345-349.
70. Norga K, Paemen L, Masure S, et al. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor d-penicillamine. Inflam Res 1995;44:529-534.
71. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vivo migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-853.
72. Stuve O, Chabot S, Jung SS, Williams G, Yong VW. Chemokine-enhanced migration of T lymphocytes is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 1997;80:38-46.
73. Pollard JD, Westland KW, Harvey GK, et al. Activated T cells of nonneuronal specificity open the blood-nerve barrier to circulating antibody. Ann Neurol 1994;37:467-475.
74. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC. Effects of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.
75. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576:203-207.
76. Moss ML, Jin SLC, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997;385:733-736.
77. Lyons PD, Benveniste EN. Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease. Glia 1998;22:103-112.
78. Leca G, Mansur SE, Bensussan A. Expression of VCAM-1 (CD106) by a subset of TCRgd-bearing lymphocyte clones. J Immunol 1995;154:1069-1077.
79. Boutros T, Croze E, Yong VW. Interferon-β is a potent promoter of nerve growth factor production by astrocytes. J Neurochem 1997;69:939-946.
80. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.